Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Modified Immune Cell
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation
Details : Modified Immune Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Transplantation.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Modified Immune Cell
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection
Details : The so-called TOL-1 study met all endpoints and demonstrated the feasibility and safety of MIC-Lx administration in inducing donor-specific tolerance in kidney transplant recipients.
Product Name : MIC-Lx
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
